{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056925","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.621813+00:00","generated_at":"2026-06-02T06:24:54.868739+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Dianthus Therapeutics Q1 net loss $13.7M; cash $377M funds into 2H 2027","bullets":["Net loss $13.7M ($0.54/share) vs $7.1M ($8.10/share) in Q1 2023.","Cash, equivalents, short-term investments $377M post $230M Jan 2024 PIPE.","Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H 2025.","MMN Phase 2 trial to start Q2 2024; CIDP Phase 2 trial in 2H 2024.","R&D expense $13.1M (incl. $0.8M SBC); G&A $5.6M (incl. $1.2M SBC)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056925","json":"https://secwatch.observer/filing/0000950170-24-056925.json","markdown":"https://secwatch.observer/filing/0000950170-24-056925.md","text":"https://secwatch.observer/filing/0000950170-24-056925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/0000950170-24-056925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/dnth-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:24:54.868739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dd1d8c31dc7129d973ff06ce9189a12b96c96b1f","claim":"Dianthus Therapeutics, Inc. /DE/ reported the quarter ended March 31, 2024 results: net income $13.7 million, EPS $0.54 net loss per share (basic and diluted).","evidence_excerpt":"Net loss for the quarter ended March 31, 2024 was $13.7 million or $0.54 net loss per share (basic and diluted)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024056925/0000950170-24-056925-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$13.7 million"},{"label":"EPS","value":"$0.54 net loss per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}